Kodiak Sciences Inc. stock exploded higher during regular trading hours, surging 178.0%. This significant move was driven by the announcement on September 28, 2026, that its lead candidates, Zenkuda and tabirafusp-ted, met their primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration. News reports from early morning on September 28, 2026, indicated the company planned to file for regulatory approval for Zenkuda, with some outlets noting the drug was on par with a rival's medicine. By midday, shares had gained over 162% following the positive trial results.